European Rare Disease & Orphan Therapeutics 2026: Sobi, Hansa, Ascendis, Calliditas, and the Orphan Cluster

Sweden concentrates the directory’s commercial rare disease cluster across four operators. Sobi (Swedish Orphan Biovitrum, Stockholm) is the directory’s commercial rare disease pharma with hematology + immunology + specialty care portfolio including Elocta / Eloctate (efmoroctocog alfa for hemophilia A), Alprolix (eftrenonacog alfa for hemophilia B), Doptelet (avatrombopag for thrombocytopenia), Gamifant (emapalumab for primary HLH), and Aspaveli / Empaveli (pegcetacoplan, partnered with Apellis for paroxysmal nocturnal hemoglobinuria, ex-US rights with Sobi). Hansa Biopharma (Lund) develops imlifidase (Idefirix), an IgG-cleaving enzyme for kidney-transplant desensitisation in highly sensitised patients (EMA conditional approval 2020) plus pipeline applications in anti-GBM disease and Guillain-Barré. Calliditas Therapeutics (Stockholm, acquired by Asahi Kasei in 2024) commercialises Tarpeyo (US, direct) / Kinpeygo (EU, via STADA partnership) targeted-release budesonide for IgA nephropathy plus orphan renal + hepatic pipeline. Ascelia Pharma (Malmö) develops Orviglance (manganese chloride tetrahydrate, oral MRI contrast agent for hepatic imaging in patients with severe renal impairment unable to receive gadolinium-based contrast — orphan-designated for hepatic-lesion detection). Together these four operators map the directory-surfaced Swedish commercial orphan portfolio.

Ascendis Pharma (Hellerup, Denmark) is the directory’s TransCon-platform rare disease operator. The TransCon prodrug-linker platform supports sustained release of approved or pipeline therapeutic moieties. Commercial products include Skytrofa (lonapegsomatropin, weekly TransCon human growth hormone for paediatric GHD, FDA-approved 2021, EMA approved 2022) and Yorvipath (palopegteriparatide, daily TransCon PTH for chronic hypoparathyroidism, FDA-approved August 2024, EMA marketing authorisation November 2024). Pipeline includes TransCon-CNP (navepegritide for achondroplasia, late-stage). Ascendis is the directory-surfaced Danish operator combining commercial rare disease revenue with a platform-extensible pipeline. Hoba Therapeutics (Copenhagen) is the adjacent Danish rare-orphan operator developing non-opioid chronic pain + sensorineural hearing loss therapeutics.

Switzerland concentrates rare neurodegenerative + autoinflammatory therapeutics across three directory operators. Gain Therapeutics (Lugano) develops allosteric small-molecule therapeutics including GT-02287 (GBA1-targeted programme for Parkinson’s with GBA1 mutation and Gaucher disease) at clinical stage. Noema Pharma (Basel) develops ex-Roche-asset rare-neurology + orphan-indication therapeutics including basimglurant (mGluR5 antagonist) and other CNS-rare candidates. AB2 Bio (Lausanne) develops tadekinig alfa (recombinant human IL-18 binding protein) at Phase 3 for monogenic IL-18-driven autoinflammatory disease (NLRC4 gain-of-function and XIAP deficiency, with prior earlier-stage exploration in Adult-onset Still’s disease). The CNS & Neuroscience Therapeutics 2026 brief covers Gain and Noema in wider CNS context.

European rare metabolic + autoimmune precision therapy spans four directory operators. Diamyd Medical (Stockholm, Sweden) develops Diamyd antigen-specific precision immunotherapy for Type 1 diabetes (DIAGNODE-3 Phase 3 trial in HLA-DR3-DQ2 patients). PolTREG (Gdansk, Poland) develops autologous and allogeneic T-regulatory cell therapy for Type 1 diabetes and multiple sclerosis (verify operating status directly with the company; PolTREG announced restructuring activity in 2024). Aurealis Therapeutics (Kuopio, Finland) develops engineered live-biotherapeutic products (lactic-acid bacteria) for diabetic foot ulcer treatment — a directory-surfaced live-biotherapeutic in rare-indication clinical development. Aranda Pharma (Kuopio, Finland) develops non-steroidal androgen-receptor inhibitors at preclinical stage for topical dermatology + hair-loss + acne, addressing a niche rare-dermatology population. The Cardiometabolic Therapeutics 2026 brief covers Diamyd and PolTREG in wider cardiometabolic context.

Two directory operators address rare infectious and orphan cystic-fibrosis indications. AlgiPharma (Sandvika, Norway) develops alginate oligomer therapeutics including OligoG for cystic fibrosis biofilm disruption and antimicrobial resistance — an orphan-indication CF programme. MinervaX (Frederiksberg, Denmark) develops a maternal Group B Streptococcus vaccine candidate (GBS-NN/NN2 fusion-protein vaccine) for prevention of neonatal GBS disease — addressing a rare but devastating neonatal infection. The European Vaccines Landscape 2026 brief covers MinervaX in wider vaccine context, and the European Anti-Infectives layer is covered in the Drug Discovery Services 2026 brief.

Several rare disease modalities sit adjacent to this brief and are covered in detail elsewhere. Cell + gene therapy ATMPs for rare disease are covered in the Cell & Gene Therapy Europe 2026 brief — including Kuopio Center for Gene and Cell Therapy (Finland), Fuse Vectors (Copenhagen), Antion Biosciences (Geneva), Cimeio Therapeutics (Basel), and the cell-therapy ATMP CDMO layer. Rare oncology + orphan-designated oncology assets are covered in the European Oncology Therapeutics 2026 brief — including Oncopeptides (Stockholm, multiple myeloma melflufen historic + post-withdrawal pipeline), Heidelberg Pharma (ATAC technology), and rare-cancer focused operators. Lundbeck (Copenhagen) and BioArctic (Stockholm) cover rare CNS indications adjacent to this brief and are mapped in the CNS Therapeutics 2026 brief.

Match the decision to the rare indication. Hematology / hemophilia / orphan immunology commercial: Sobi (Stockholm). Kidney transplant desensitisation: Hansa Biopharma (Lund, imlifidase). IgA nephropathy + orphan renal/hepatic: Calliditas Therapeutics (Stockholm). Orphan-designated oral hepatic MRI contrast for renally impaired patients: Ascelia Pharma (Malmö, Orviglance). TransCon-platform sustained-release rare disease (GHD, hypoparathyroidism, achondroplasia): Ascendis Pharma (Hellerup). Non-opioid chronic pain / sensorineural hearing loss: Hoba Therapeutics (Copenhagen). Allosteric small-molecule rare neurodegenerative (Gaucher, Parkinson’s GBA1): Gain Therapeutics (Lugano). Ex-Roche-asset rare CNS + neurology: Noema Pharma (Basel). IL-18 autoinflammatory disease: AB2 Bio (Lausanne). Type 1 diabetes precision immunotherapy: Diamyd Medical (Stockholm). T-regulatory cell therapy for autoimmune (T1D, MS): PolTREG (Gdansk). Live-biotherapeutic for diabetic foot ulcer: Aurealis Therapeutics (Kuopio). Topical dermatology androgen-receptor: Aranda Pharma (Kuopio). Cystic fibrosis biofilm disruption: AlgiPharma (Sandvika). Maternal Group B Strep vaccine: MinervaX (Frederiksberg). The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.